Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2862277 in Patients Undergoing Oesophagectomy
NCT02221037Phase 2Terminated
- Sponsor
- GSK
- Start
- Apr 2015
- Primary completion
- Jun 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) comparing GSK2862277 with Placebo (2 arms). Primary endpoint: Pulmonary Vascular Permeability Index. Started Apr 2015; status: terminated.
02
Drugs
GSK2862277
03
Conditions
acute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02221037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221037.